Rhythm PharmaceuticalsRYTM
RYTM
About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Employees: 283
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
521% more call options, than puts
Call options by funds: $21.5M | Put options by funds: $3.46M
130% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 20
23% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 69
12% more funds holding
Funds holding: 203 [Q4 2024] → 228 (+25) [Q1 2025]
3.4% less ownership
Funds ownership: 105.63% [Q4 2024] → 102.23% (-3.4%) [Q1 2025]
6% less capital invested
Capital invested by funds: $3.63B [Q4 2024] → $3.43B (-$208M) [Q1 2025]
36% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 7 (-4) [Q1 2025]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$84
1%
downside
Avg. target
$102
20%
upside
High target
$129
52%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Whitney Ijem | 24%upside $105 | Buy Maintained | 18 Jul 2025 |
Leerink Partners Faisal Khurshid | 20%upside $102 | Outperform Maintained | 10 Jul 2025 |
Oppenheimer Leland Gershell | 30%upside $110 | Outperform Maintained | 10 Jul 2025 |
B of A Securities Tazeen Ahmad | 12%upside $95 | Buy Maintained | 10 Jul 2025 |
Wells Fargo Derek Archila | 52%upside $129 | Overweight Maintained | 10 Jul 2025 |
Financial journalist opinion
Based on 13 articles about RYTM published over the past 30 days
Negative
Zacks Investment Research
1 day ago
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.
Positive
The Motley Fool
1 week ago
Should You Invest in This Under-the-Radar Weight Loss Stock?
If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two are the undisputed leaders in the field.
Neutral
The Motley Fool
1 week ago
Rhythm Pharmaceuticals CFO Sells 42,120 Shares
Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals (RYTM -0.04%), reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in post-transaction holdings of 116,915 shares.
Neutral
GlobeNewsWire
2 weeks ago
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced data from three new presentations on the Company's clinical programs for acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Acquired hypothalamic obesity is a rare but serious condition caused by damage to the hypothalamic region of the brain, which includes the melanocortin-4 receptor (MC4R) pathway.
Positive
Seeking Alpha
2 weeks ago
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market
Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market opportunity with minimal competition, as MC4R agonists address the root cause, unlike GLP-1s. Pipeline expansion, including oral and weekly MC4R agonists, positions Rhythm for long-term market dominance in rare obesity beyond 2040.
Positive
Zacks Investment Research
2 weeks ago
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Positive
Zacks Investment Research
2 weeks ago
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
GlobeNewsWire
3 weeks ago
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced the pricing of its upsized public offering of 2,058,824 shares of its common stock at a public offering price of $85.00 per share. In addition, Rhythm also granted the underwriters a 30-day option to purchase up to an additional 308,823 shares of common stock at the public offering price, less the underwriting discounts and commissions.
Neutral
GlobeNewsWire
3 weeks ago
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discounts and commissions.
Charts implemented using Lightweight Charts™